Seres Therapeutics to Host Third Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2021

Rhea-AI Summary

Seres Therapeutics (Nasdaq: MCRB) will host a conference call and audio webcast on November 10, 2021, at 8:30 a.m. ET to discuss its third quarter 2021 results and provide a general business update. Interested parties can join via phone or the company's website. The firm is noted for its breakthrough microbiome therapeutics, particularly the SER-109 program, which has achieved positive clinical results for recurrent C. difficile infection. This program has received Breakthrough Therapy and Orphan Drug designations from the FDA.

Positive

• SER-109 program achieved positive pivotal clinical results for recurrent C. difficile infection.
• SER-109 has received Breakthrough Therapy and Orphan Drug designations from the FDA.
• Active evaluation of SER-301 and SER-155 in Phase 1b studies for ulcerative colitis and gastrointestinal infections, respectively.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on November 10, 2021 at 8:30 a.m. ET to discuss third quarter 2021 results and provide a general business update.

To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 1275436. To join the live webcast, please visit the “Investors and Media” section of the Seres website at www.serestherapeutics.com.

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia and graft-versus-host disease. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005113/en/

PR

Kristin Ainsworth

kainsworth@serestherapeutics.com

IR

Carlo Tanzi, Ph.D.

ctanzi@serestherapeutics.com

Source: Seres Therapeutics, Inc.

FAQ

When will Seres Therapeutics announce their Q3 2021 results?

Seres Therapeutics will discuss their Q3 2021 results on November 10, 2021.

What is the significance of the SER-109 program for Seres Therapeutics?

The SER-109 program is the first targeted microbiome drug to achieve positive pivotal clinical results, highlighting its potential as a first-in-class therapeutic.

What is the ticker symbol for Seres Therapeutics?

The ticker symbol for Seres Therapeutics is MCRB.

How can I access the conference call for Seres Therapeutics?

You can dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference conference ID 1275436 to access the call.